Helen Remotti
Columbia University
117 Papers
510 Citations
Helen Remotti is an academic researcher from Columbia University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 36, co-authored 109 publications. Previous affiliations of Helen Remotti include University of California, Los Angeles & Armed Forces Institute of Pathology.
Chat about Author
Papers
Diagnosis of gastrointestinal stromal tumors: A consensus approach.
Christopher D.M. Fletcher,Jules J. Berman,Christopher L. Corless,Fred Gorstein,Jerzy Lasota,B. Jack Longley,Markku Miettinen,Timothy J. O'Leary,Helen Remotti,Brian P. Rubin,Barry M. Shmookler,Leslie H. Sobin,Sharon W. Weiss +12 more
TL;DR: Key elements of the consensus are the defining role of KIT immunopositivity in diagnosis and a proposed scheme for estimating metastatic risk in these lesions, based on tumor size and mitotic count, recognizing that it is probably unwise to use the definitive term "benign" for any GIST, at least at the present time.
3.7K
CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum
Helene Zinszner,Masahiko Kuroda,Xiaozhong Wang,Nikoleta Batchvarova,Richard T. Lightfoot,Helen Remotti,James L. Stevens,David Ron +7 more
TL;DR: Compared with the wild type, mouse embryonic fibroblasts derived from chop -/- animals exhibited significantly less programmed cell death when challenged with agents that perturb ER function, and the proximal tubule epithelium of chop -/+ animals exhibited fourfold lower levels of TUNEL-positive cells, and significantly less evidence for subsequent regeneration.
•Journal Article
Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal.
TL;DR: It is concluded that gastrointestinal stromal tumors show striking morphological and immunophenotypic similarities with ICC and that they may originate from stem cells that differentiate toward a pacemaker cell phenotype and it is proposed that the noncommittal name "gastrointestinal stromic tumor" be replaced by gastrointestinal pacemaker Cell tumor.
1.8K
Diagnosis of Gastrointestinal Stromal Tumors:A Consensus Approach
Christopher D.M. Fletcher,Jules J. Berman,Christopher L. Corless,Fred Gorstein,Jerzy Lasota,B. Jack Longley,Markku Miettinen,Timothy J. O'Leary,Helen Remotti,Brian P. Rubin,Barry M. Shmookler,Leslie H. Sobin,Sharon W. Weiss +12 more
TL;DR: Key elements of the consensus are the defining role of KIT immunopositivity indiagnosis and a proposed scheme for estimating metastatic risk in these lesions, based on tumor size and mitotic count, recognizing that it is probably unwise to use the definitive term benign for any GIST, at least at the present time.
Long-lived intestinal tuft cells serve as colon cancer–initiating cells
C. Benedikt Westphalen,Samuel Asfaha,Yoku Hayakawa,Yoshihiro Takemoto,Dana J. Lukin,Andreas H. Nuber,Anna Brandtner,Wanda Setlik,Helen Remotti,Ashlesha Muley,Xiaowei Chen,Randal May,Courtney W. Houchen,James G. Fox,Michael D. Gershon,Michael Quante,Timothy C. Wang +16 more
TL;DR: An intestinal DCLK1⁺ tuft cell population is defined that is long lived, quiescent, and important for intestinal homeostasis and regeneration, but are activated by tissue injury and can serve to initiate colon cancer.